Gregory Mcbride (jasonprice8)

The birth of a child affected by a threatened abortion (TAB) in utero is associated with autism spectrum disorder; association with other neurological disorders is unknown. This nationwide registry-based cohort study included singletons live-born in Denmark (1979-2010), followed through 2016. The outcomes were epilepsy, cerebral palsy (CP) and attention-deficit/hyperactivity disorder (ADHD). We used Cox regression to compute hazard ratios (HRs), adjusted for birth year, birth order, parental age, morbidity, medication use and maternal socio-economic factors. To remove time-invariant family-shared confounding, we applied sibling analyses. The study population included 1 864 221 singletons live-born in 1979-2010. Among the TAB-affected children (N = 59 134) vs TAB-unaffected children, at the end of follow-up, the cumulative incidence was 2.2% vs 1.6% for epilepsy, 0.4% vs 0.2% for CP and 5.5% vs 4.2% for ADHD (for children born in 1995-2010). The adjusted HRs were 1.25 [95% confidence interval (CI) 1.16-1.34] for epilepsy, 1.42 (95% CI 1.20-1.68) for CP and 1.21 (95% CI 1.14-1.29) for ADHD. In the sibling design, the adjusted HRs were unity for epilepsy (full siblings 0.96, 95% CI 0.82-1.12; maternal 1.04, 95% CI 0.90-1.20; paternal 1.08, 95% CI 0.93-1.25) and ADHD (full 1.08, 95% CI 0.92-1.27; maternal 1.04, 95% CI 0.90-1.20; paternal 1.08, 95% CI 0.93-1.25). For CP, HRs shifted away from unity among sibling pairs (full 2.92, 95% CI 1.33-6.39; maternal 2.03, 95% CI 1.15-3.57; paternal 3.28, 95% CI 1.36-7.91). The birth of a child affected by TAB in utero was associated with a greater risk of CP, but not epilepsy or ADHD. The birth of a child affected by TAB in utero was associated with a greater risk of CP, but not epilepsy or ADHD. COVID-19 has strained healthcare systems with patient hospitalizations and deaths. Anti-spike monoclonal antibodies, including bamlanivimab, have demonstrated reduction in hospitalization rates in clinical trials, yet real-world evidence is lacking. We conducted a retrospective case-control study across a single healthcare system of non-hospitalized patients, age 18 years or older, with documented positive SARS-CoV-2 testing, risk factors for severe COVID-19, and referrals for bamlanivimab via emergency use authorization. Cases were defined as patients who received bamlanivimab; contemporary controls had a referral order placed but did not receive bamlanivimab. The primary outcome was 30-day hospitalization rate from initial positive SARS-CoV-2 PCR. Descriptive statistics, including Chi-square and Mann-Whitney U test, were performed. Multivariable logistic regression was used for adjusted analysis to evaluate independent associations with 30-day hospitalization. Between November 20, 2020 and January 19,gainst hospitalization. Approximately 7.3 million births occur annually among adolescents in low- and middle-income countries. Pregnant adolescents constitute a nutritionally vulnerable group that could benefit from intervention to mitigate the mortality and adverse birth outcomes associated with adolescent pregnancy. The aim of this systematic review and meta-analysis was to assess the following (1) the effect of multiple-micronutrient (MMN) supplementation vs iron and folic acid (IFA) supplementation among adolescents on maternal morbidity, birth outcomes, and mortality outcomes, (2) the effects of MMN supplementation in adolescents compared with the effects in adult women, and (3) the effect modification, if any, of MMN supplementation by baseline and geographic characteristics of adolescents. MEDLINE and Cochrane databases were searched, along with the reference lists of relevant reviews. Multiple-micronutrient supplementation trials in pregnancy that were conducted in a low- or middle-income country and had included at .95) when compared with IFA supplementation. click here The eff